For some patients, targeted therapy is their best shot. The Molecular Tumor Board at DCI is matching more and more patients to approved therapies and clinical trials.
DCI was invited to join the elite international AACR Project GENIE consortium, whose registry contains clinical-grade cancer genomic sequencing data from nearly 71,000 patients & 80 major cancer types.
Wrestling with “next generation sequencing," this Mr. T is helping Duke oncologists utilize a Molecular Tumor Board to deliver patient centered precision cancer medicine.